GlassScriptPhysician profile
Nicole Omey
NPI 1922738020
$2,553.57
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $416 · 2023: $1,439 · 2024: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $524.52 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $359.85 | 2023-2024 | |
| Lilly USA, LLC | $297.89 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Exact Sciences Corporation | $234.89 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $174.99 | 2023-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.76 | 2022-2023 | Jardiance, Ofev |
| Abbott Laboratories | $121.21 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $112.00 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $89.36 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $88.27 | 2023-2024 | Airsupra, Breztri |
| Pfizer INC. | $79.64 | 2023-2024 | |
| Mylan Specialty L.P. | $69.62 | 2023 | Yupelri |
| Dexcom, INC. | $44.29 | 2023-2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $40.79 | 2024 | Immunocap |
| Amgen INC. | $35.29 | 2023 | Prolia, Evenity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.17 | 2023 | Xifaxan |
| Endogastric Solutions, INC | $20.26 | 2023 | Esophyx |
| Janssen Pharmaceuticals, INC | $18.46 | 2023 | Spravato |
| Astellas Pharma US INC | $18.12 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $17.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.06 | 2022 | |
| Merck Sharp & Dohme LLC | $14.71 | 2022 | |
| Shield Therapeutics INC | $13.33 | 2023 | Accrufer |
| Sanofi-Aventis U.S. LLC | $13.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Omey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.